Literature DB >> 947411

Responsiveness of isolated dog veins to bradykinin and other bioactive peptides: distribution of sensitivity to bradykinin and possible correlation with genesis of the venous system.

H Tsuru, N Ishikawa, T Shigei.   

Abstract

Contractile responses of isolated dog veins to bradykinin were studied. Responses to norepinephrine were taken as standards. According to their sensitivity to bradykinin, the veins obtained from 14 sites of the venous system were divided into two groups, while all the veins were almost uniform in their sensitivity to norepinephrine. One group has high sensitivity to bradykinin and the other has low sensitivity. The former includes the pulmonary, hepatic, splenic, and portal veins, the anterior vena cava, and the upper and the middle divisions of the posterior vena cava. The latter includes the external jugular, cephalic, azygos, femoral, and saphenous veins, and the lower division of the posterior vena cava. The responses of the renal vein were intermediate. A striking correlation was noted between the distribution of bradykinin sensitivity and the genesis of the venous system. Five bioactive peptides other than bradykinin were also studied. Only angiotensin induced contraction in some preparation, but, as a whole, caerulein, eledoisin-related peptide, oxytocin and vasopressin rarely showed contractile activity.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 947411     DOI: 10.1159/000158092

Source DB:  PubMed          Journal:  Blood Vessels        ISSN: 0303-6847


  2 in total

1.  Mediation of bradykinin-induced contraction in canine veins via thromboxane/prostaglandin endoperoxide receptor activation.

Authors:  M O Aksoy; C Harakal; J B Smith; G J Stewart; C R Zerweck
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

2.  Extrinsic innervation of the canine abdominal vena cava and the origin of cholinergic vasoconstrictor nerves.

Authors:  Y Nakazato; A Ohga; T Shigei; T Uematsu
Journal:  J Physiol       Date:  1982-07       Impact factor: 5.182

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.